Adjuvant interferon therapy for melanoma: high-dose, low-dose, no dose, which dose?

Topical resiquimod elicits systemic protection and improves anti-PD1 therapy in melanoma via priming of CD8+ T cells.

Cancer immunology research·2026

Melanoma-patient-derived xenograft multi-omics resource melPDomiX maps gain- and loss-of-function alterations.

Cell reports·2026

A longitudinal, multi-omic atlas reveals the emergence of a spatially organized immunosuppressive ecosystem in resistant melanoma.

Cell reports. Medicine·2026

Outcomes after SRS and ipilimumab plus nivolumab for melanoma brain metastases following prior immune checkpoint inhibitor or targeted therapy.

The oncologist·2026

Accuracy of Sentinel Lymph Node Biopsy to Predict Nodal Metastasis in Head and Neck Merkel Cell Carcinoma.

JAMA otolaryngology-- head & neck surgery·2026

Antigen-specific profiling identifies T-bet+ melanoma-specific CD8+ T cells associated with response to neoadjuvant PD-1 blockade.

Cancer cell·2026

Therapy for Stage IV Non-Small Cell Lung Cancer With Driver Alterations: ASCO Living Guideline, Version 2026.3.3.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2026

Immunotherapy and Targeted Therapy for Advanced Gastroesophageal Cancer: ASCO Living Guideline, Version 2026.1.2.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2026

Laser Interstitial Thermal Therapy for Brain Tumors: A Prospective Multicenter Analysis of Patients From the LAANTERN Study.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2026

Mosunetuzumab With Response-Adapted Polatuzumab Vedotin and Obinutuzumab in Untreated Indolent B-Cell Non-Hodgkin Lymphoma.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2026

COMBI-I: Long-Term Overall Survival With Spartalizumab Plus Dabrafenib and Trametinib in BRAF V600-Mutant Advanced Melanoma.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2026

Prognostic and Predictive Effect of Age in Molecularly Defined Lower-Grade Gliomas.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2026

Erratum to 'Clinical and Immunologic Features of Primary Enteric-Type Thymic Adenocarcinomas: A Rare Variant of a Rare Cancer' [JTO Clinical and Research Reports 7 (2026) 101019].

JTO clinical and research reports·2026

Mathematical and Mouse Models Identify Regulatory T Cell Influx as A Key Determinant of Acquired Resistance to PD-1 Immunotherapy.

Cancer research·2026

Peripheral cytokine distinguish recent from Mycobacterium tuberculosis infection and active tuberculosis.

Frontiers in microbiology·2026

Hypoxia induces cytotoxicity and suppresses cytokine production by CD8□ T cells in cutaneous leishmaniasis.

bioRxiv : the preprint server for biology·2026

Tumor-specific CD4 T cells cooperate with myeloid cells to remodel the pancreatic tumor microenvironment and enable effective immunotherapy.

bioRxiv : the preprint server for biology·2026

PD-L1 restrains T-cell immunity in Nile tilapia by suppressing activation-induced fatty acid synthesis.

Journal of immunology (Baltimore, Md. : 1950)·2026

Related Experiment Videos

Adjuvant interferon therapy for melanoma: high-dose, low-dose, no dose, which dose?

Related Concept Videos

Topical resiquimod elicits systemic protection and improves anti-PD1 therapy in melanoma via priming of CD8+ T cells.

Melanoma-patient-derived xenograft multi-omics resource melPDomiX maps gain- and loss-of-function alterations.

A longitudinal, multi-omic atlas reveals the emergence of a spatially organized immunosuppressive ecosystem in resistant melanoma.

Outcomes after SRS and ipilimumab plus nivolumab for melanoma brain metastases following prior immune checkpoint inhibitor or targeted therapy.

Accuracy of Sentinel Lymph Node Biopsy to Predict Nodal Metastasis in Head and Neck Merkel Cell Carcinoma.

Antigen-specific profiling identifies T-bet+ melanoma-specific CD8+ T cells associated with response to neoadjuvant PD-1 blockade.

Therapy for Stage IV Non-Small Cell Lung Cancer With Driver Alterations: ASCO Living Guideline, Version 2026.3.3.

Immunotherapy and Targeted Therapy for Advanced Gastroesophageal Cancer: ASCO Living Guideline, Version 2026.1.2.

Laser Interstitial Thermal Therapy for Brain Tumors: A Prospective Multicenter Analysis of Patients From the LAANTERN Study.

Mosunetuzumab With Response-Adapted Polatuzumab Vedotin and Obinutuzumab in Untreated Indolent B-Cell Non-Hodgkin Lymphoma.

COMBI-I: Long-Term Overall Survival With Spartalizumab Plus Dabrafenib and Trametinib in BRAF V600-Mutant Advanced Melanoma.

Prognostic and Predictive Effect of Age in Molecularly Defined Lower-Grade Gliomas.

Erratum to 'Clinical and Immunologic Features of Primary Enteric-Type Thymic Adenocarcinomas: A Rare Variant of a Rare Cancer' [JTO Clinical and Research Reports 7 (2026) 101019].

Mathematical and Mouse Models Identify Regulatory T Cell Influx as A Key Determinant of Acquired Resistance to PD-1 Immunotherapy.

Peripheral cytokine distinguish recent from Mycobacterium tuberculosis infection and active tuberculosis.

Hypoxia induces cytotoxicity and suppresses cytokine production by CD8□ T cells in cutaneous leishmaniasis.

Tumor-specific CD4 T cells cooperate with myeloid cells to remodel the pancreatic tumor microenvironment and enable effective immunotherapy.

PD-L1 restrains T-cell immunity in Nile tilapia by suppressing activation-induced fatty acid synthesis.

Related Experiment Videos

Adjuvant interferon therapy for melanoma: high-dose, low-dose, no dose, which dose?

Related Concept Videos

Related Articles